Lantheus (NASDAQ:LNTH) Issues Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25, FiscalAI reports. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter last year, the business posted $1.57 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis.

Lantheus Stock Performance

Shares of Lantheus stock opened at $100.95 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.64 and a debt-to-equity ratio of 0.43. The stock’s fifty day moving average price is $104.09 and its 200-day moving average price is $87.98. The firm has a market cap of $6.57 billion, a P/E ratio of 24.38 and a beta of -0.03. Lantheus has a 12 month low of $49.67 and a 12 month high of $111.86.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LNTH. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a report on Monday. Weiss Ratings upgraded shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 31st. Mizuho dropped their price target on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. Finally, William Blair set a $102.50 price target on shares of Lantheus in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $108.11.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LNTH. EverSource Wealth Advisors LLC boosted its stake in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares in the last quarter. First Trust Advisors LP raised its stake in Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after buying an additional 19,008 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 500 shares during the period. Daiwa Securities Group Inc. lifted its holdings in Lantheus by 88.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 1,591 shares during the period. Finally, Osterweis Capital Management Inc. bought a new stake in Lantheus during the 2nd quarter valued at $36,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.